Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 11335 | 11.54 |
09:36 ET | 200 | 11.62 |
09:38 ET | 2015 | 11.56 |
09:39 ET | 900 | 11.62 |
09:43 ET | 1960 | 11.7 |
09:45 ET | 2000 | 11.63 |
09:48 ET | 4338 | 11.7 |
09:52 ET | 600 | 11.68 |
09:56 ET | 400 | 11.685 |
09:57 ET | 72522 | 11.8368 |
09:59 ET | 12798 | 11.78 |
10:01 ET | 400 | 11.785 |
10:03 ET | 11809 | 11.67 |
10:06 ET | 900 | 11.65 |
10:08 ET | 2612 | 11.6 |
10:10 ET | 1206 | 11.575 |
10:12 ET | 800 | 11.58 |
10:14 ET | 4784 | 11.52 |
10:15 ET | 8065 | 11.545 |
10:17 ET | 700 | 11.57 |
10:19 ET | 1300 | 11.595 |
10:21 ET | 30996 | 11.78 |
10:24 ET | 7012 | 11.72 |
10:26 ET | 1062 | 11.74 |
10:28 ET | 6125 | 11.7306 |
10:30 ET | 1926 | 11.69 |
10:32 ET | 1000 | 11.685 |
10:33 ET | 1700 | 11.715 |
10:35 ET | 7824 | 11.725 |
10:37 ET | 2000 | 11.81 |
10:39 ET | 1752 | 11.81 |
10:42 ET | 800 | 11.79 |
10:44 ET | 4124 | 11.825 |
10:46 ET | 700 | 11.81 |
10:48 ET | 1900 | 11.845 |
10:50 ET | 1500 | 11.83 |
10:51 ET | 3414 | 11.83 |
10:53 ET | 9860 | 11.765 |
10:55 ET | 2812 | 11.77 |
10:57 ET | 4679 | 11.825 |
11:00 ET | 5148 | 11.85 |
11:02 ET | 1311 | 11.8758 |
11:04 ET | 5990 | 11.91 |
11:06 ET | 1110 | 11.92 |
11:08 ET | 2080 | 11.99 |
11:09 ET | 2956 | 11.985 |
11:11 ET | 33710 | 11.92 |
11:13 ET | 825 | 11.93 |
11:15 ET | 2048 | 11.89 |
11:18 ET | 1150 | 11.8 |
11:20 ET | 527 | 11.83 |
11:22 ET | 1072 | 11.83 |
11:24 ET | 4793 | 11.8 |
11:26 ET | 1076 | 11.825 |
11:27 ET | 200 | 11.825 |
11:29 ET | 3600 | 11.83 |
11:31 ET | 400 | 11.83 |
11:33 ET | 2685 | 11.92 |
11:36 ET | 300 | 11.92 |
11:38 ET | 1700 | 11.92 |
11:40 ET | 500 | 11.94 |
11:42 ET | 1000 | 11.95 |
11:44 ET | 1700 | 11.935 |
11:45 ET | 100 | 11.92 |
11:47 ET | 1080 | 11.94 |
11:49 ET | 2093 | 11.94 |
11:51 ET | 1904 | 11.92 |
11:54 ET | 1400 | 11.915 |
11:56 ET | 100 | 11.915 |
11:58 ET | 1050 | 11.94 |
12:00 ET | 3849 | 11.92 |
12:02 ET | 200 | 11.92 |
12:03 ET | 200 | 11.925 |
12:05 ET | 1200 | 11.93 |
12:07 ET | 1508 | 11.93 |
12:09 ET | 400 | 11.95 |
12:12 ET | 3713 | 11.985 |
12:14 ET | 4148 | 12.01 |
12:16 ET | 4096 | 11.99 |
12:18 ET | 8920 | 11.92 |
12:20 ET | 2399 | 11.89 |
12:21 ET | 300 | 11.925 |
12:23 ET | 100 | 11.9 |
12:25 ET | 851 | 11.92 |
12:27 ET | 1600 | 11.91 |
12:32 ET | 700 | 11.88 |
12:34 ET | 1800 | 11.91 |
12:36 ET | 14550 | 11.93 |
12:38 ET | 1034 | 11.92 |
12:39 ET | 400 | 11.9 |
12:43 ET | 1710 | 11.82 |
12:45 ET | 800 | 11.74 |
12:48 ET | 500 | 11.75 |
12:50 ET | 100 | 11.775 |
12:52 ET | 400 | 11.75 |
12:54 ET | 200 | 11.775 |
12:56 ET | 300 | 11.75 |
12:57 ET | 200 | 11.775 |
12:59 ET | 3204 | 11.775 |
01:03 ET | 800 | 11.77 |
01:06 ET | 400 | 11.77 |
01:08 ET | 800 | 11.77 |
01:10 ET | 2159 | 11.835 |
01:12 ET | 3512 | 11.8 |
01:14 ET | 300 | 11.81 |
01:15 ET | 300 | 11.8 |
01:17 ET | 1406 | 11.83 |
01:19 ET | 2498 | 11.82 |
01:21 ET | 600 | 11.815 |
01:24 ET | 300 | 11.82 |
01:28 ET | 900 | 11.8 |
01:30 ET | 732 | 11.79 |
01:32 ET | 1300 | 11.77 |
01:33 ET | 400 | 11.785 |
01:35 ET | 500 | 11.785 |
01:37 ET | 2217 | 11.805 |
01:39 ET | 200 | 11.805 |
01:42 ET | 1900 | 11.82 |
01:44 ET | 1300 | 11.84 |
01:46 ET | 300 | 11.86 |
01:48 ET | 300 | 11.87 |
01:50 ET | 1611 | 11.86 |
01:51 ET | 331 | 11.85 |
01:53 ET | 400 | 11.865 |
01:55 ET | 400 | 11.88 |
01:57 ET | 200 | 11.87 |
02:00 ET | 350 | 11.88 |
02:02 ET | 2173 | 11.87 |
02:04 ET | 851 | 11.84 |
02:06 ET | 650 | 11.82 |
02:08 ET | 200 | 11.81 |
02:09 ET | 200 | 11.83 |
02:11 ET | 609 | 11.81 |
02:13 ET | 491 | 11.8143 |
02:15 ET | 400 | 11.81 |
02:20 ET | 100 | 11.81 |
02:22 ET | 2170 | 11.8071 |
02:24 ET | 200 | 11.78 |
02:26 ET | 1296 | 11.8036 |
02:27 ET | 700 | 11.85 |
02:29 ET | 700 | 11.835 |
02:31 ET | 2300 | 11.855 |
02:33 ET | 700 | 11.88 |
02:36 ET | 6631 | 11.79 |
02:38 ET | 700 | 11.77 |
02:40 ET | 800 | 11.805 |
02:44 ET | 1764 | 11.87 |
02:45 ET | 3826 | 11.83 |
02:47 ET | 1000 | 11.83 |
02:49 ET | 200 | 11.85 |
02:51 ET | 200 | 11.84 |
02:54 ET | 3155 | 11.87 |
02:56 ET | 1200 | 11.87 |
02:58 ET | 100 | 11.88 |
03:00 ET | 3608 | 11.875 |
03:02 ET | 1100 | 11.88 |
03:03 ET | 1957 | 11.87 |
03:05 ET | 8670 | 11.89 |
03:07 ET | 4556 | 11.84 |
03:09 ET | 1136 | 11.84 |
03:12 ET | 2100 | 11.85 |
03:14 ET | 3331 | 11.84 |
03:16 ET | 2884 | 11.83 |
03:18 ET | 500 | 11.83 |
03:20 ET | 2014 | 11.84 |
03:21 ET | 2955 | 11.82 |
03:23 ET | 2645 | 11.84 |
03:25 ET | 225 | 11.84 |
03:27 ET | 3150 | 11.85 |
03:30 ET | 1534 | 11.85 |
03:32 ET | 12957 | 11.83 |
03:34 ET | 889 | 11.83 |
03:36 ET | 3517 | 11.83 |
03:38 ET | 2300 | 11.82 |
03:39 ET | 300 | 11.83 |
03:41 ET | 5103 | 11.82 |
03:43 ET | 3178 | 11.825 |
03:45 ET | 4400 | 11.83 |
03:48 ET | 2518 | 11.82 |
03:50 ET | 5616 | 11.8 |
03:52 ET | 3130 | 11.85 |
03:54 ET | 8463 | 11.85 |
03:56 ET | 18607 | 11.845 |
03:57 ET | 24788 | 11.84 |
03:59 ET | 27167 | 11.88 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 1.9B | -7.7x | --- |
Keros Therapeutics Inc | 1.8B | -10.1x | --- |
Akero Therapeutics Inc | 1.9B | -8.7x | --- |
Verona Pharma PLC | 1.7B | -28.2x | --- |
Soleno Therapeutics Inc | 1.7B | -19.2x | --- |
Kura Oncology Inc | 1.7B | -10.7x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -7.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.